Pharma Pulse 7/26/24: Research Shows Promise Toward Universal Flu Vaccine, AI Struggles with Math & more

Guiding Principles for Trial Participant Communication

Nine tips to help sites close the information and understanding gaps in their dealings with patients.

Research Results Show Promise Toward Development of a Universal Influenza Vaccine

Despite the century-long period of virus evolution, 6 of the 11 primates that received a cytomegalovirus-expressed flu vaccine survived the exposure to H5N1 flu.

AI Can Write Poetry, but It Struggles With Math

A.I.’s math problem reflects how much the new technology is a break with computing’s past.

European Commission Approves Pfizer’s DURVEQTIX

Pfizer Inc. announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.
Austin Gaines on LinkedIn

Looking forward to hearing thought leaders like Matt Wilkins share his perspective!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs